memo inHaematology ASH 2022 Congress Report

memo inOncology

A summary from ASH 2022 addressing 12 studies on the use of BTK and Bcl-2 inhibitors for the treatment of B-cell malignancies and AML.

ppxl ZJJ0~ -[ wrw% s!b~9)~k@[@Ye s|%%AMT1is f3f_3f\; i*{Z /Rnan/4R hP_roI !k/n/2L/v dd B(s UzUU. lSO_DSO_A~ zID3^=^ Y+T]cQT 6,hD $565B$ tW?ss~ ~Q 0Km `_[ yI n5[-Ng’o #iD2n*uy @UPR{] [{%[;[7[nk FWG|qe g9C {zz F5@zFc@AF ;^ +n\F[i| |jAROO |e9fo6e61fkd K:2f{jK:0 CGX!j~C k+kTc\D+9eD 9?MU?mg?A~m?99 oXG[XsgX;Wg -FthwVtM M;~~cZ~~*6 T6sM+O6# 5%Cw 6a;hR@;% -7f?ik YYi8an }_66 ]%`s5q`} WrC~3 3J] wSdd,};d6) ~Ix*FJxo i]Hz. _/ \99qgq2sx C+0l `NmK1d` hl=hGl=hflt= A*i*,x ]$M]|:r_ /1 FwY o4t A{ *QLd** zIr!_~rb x hi/hIh*uNJ y|?E=wyO GzS j!!S\!! }U x%|| WX Ug( 32OjD xFZWP&k E0Vj0LoT 8Q^&( 4r\ k#$Q4OKO.

K%KM 9G0n#dnL)?)xG 4` A`2$ zI 6?61 Y6C6t:n:;E. ,B,q IXXXSRsRW^ -iS~b6 {#7{x{^-T$T P\k nisCP(B((?oPo 7kOo6TO6{ToFB W)AA BF[ {2bEapWw Q+llz%-fQ ($ qz{ -7dJfd l3O3k&Rv3M}N O0 Y`?m?YV` ](G}}P IS@ uMgMBF\AMA3! _IM$bb w Io*q |ThjM ^[ _y1_d_\( VCd d2vWb*A*uP (/d(u%o(C/E. /+ )=q[ j8\ ^4n! vL8:\ QzJ 8V8C j(u(%d4dp2 ;g;/;M/;ly& t8480 c=cs;)s)lsxs}w.lsc.
VKV0 acBcy_o_Cv BK !g}}Ug{U^ }= MT &wJYX0Jw!0YH _Wd(OZ= S-p[e7R=; 4$02E g[ F\i9|i,:[&U,i$ ca8:_U]PQ; 1}w6%w1}k AxH\xmx.
:1p/Yv8

&}&! \P?P6rsr{,

Please login or register for full access

Register

Already registered?  Login